1Crino L,Conte P,De Marinis F,et al.A randomized trial of gemcitabine cisplatin versus mitomycin,ifosfamide and cisplatin(MIC) in advanced non-small cell lung cance(NSCLC): a multicenter phase Ⅲ study[J].Proc Am Soc Clin Oncol,1998,17:455(abstr 1750)
2Iaffaioli RV,Tortoriello A,Santangelo M,et,al: Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer[J].Clin Oncol,2000,12(4): 251
3Pace E,Melis M,Siena L,et al.Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer(NSCLC) cell lines[J].Cancer Chemother Pharmacol,2000,46(6): 467
4Van Moorsel CJA,Peters G,Pinedo HM.Gemcitabine: Future prospects of single-agent and combination studies[J].Oncologist,1997,2:127
5von der Maase H.Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer[J].Eur J Cancer,2000,36(Suppl):213
6Feliu J,Lopez Alvarez MP,Jaraiz MA,et al.Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma[J].Cancer,2000,89(8): 1706
2Grillo-Lopez AJ, Cheson BD, Homing SJ, et al. Response criteria for NHL:importance of 'normal' lymph node size and correlations with re- sponse rates[J]. Ann Oncol,2000,11 (4) :399-408.
3McLaughlin P, Grillo-Lopeza J, Link BK, et al. Rituxmab chimeric anti- CD20 monoclonal antibody therapy fo relapsed indolent lymphoma:half of patients respond to a four-dose treatment program [ J ]. J Clin Oncol, 1998 , 16 ( 8 ) : 2825-33.
4Coiftier B, Haioun C, Ketrerer N, et al. Rituximab ( anti-CD20 mono- clonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase Ⅱ study[J]. Blood,1998,92 (6) :1927-32.
5Park BB, Kim WS, Eom HS, et al. Salvage therapy with gemcitabine, ifos- famide,dexamethasone,and oxaliplatin(GIDOX) for B-cell non Hodgkin' s lymphoma: a consortium for improving survival of lymphoma (CISL) trial[ J]. Invest New Drugs ,2011 ,29 (1) :154-60.
6Bergman .AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P - glyeoprotein and multidrug resistance - asso- ciated protein - overexpressing human cancer cell lines [ J ]. Br J Cancer,2003,88 : 1963 - 1970.
7Fossa A, Santoro A, Hiddemann W, et al. Gemeitabine as a single agent in the treatment of relapsed or refractory aggressive non - Hodgkin lymphoma [ J ]. J Clin Oncol, 1999,17:3786 - 3792.
8Peters GJ, Bergman AM, Ruiz van Haperen VW, et al . Interaction between eisplatin and gemcitabine in vitro and in vivo [ J ]. Semin Oncol, 1995,22 (4suppl 11 ) :72 - 79.
9Bergman AM, Ruiz Van Haperen VW, Veerman G, et al. Synergisticinteraction between cisplatin and gemcitabine in vitro [ J 1. Clin Cancer Res,1996,2(3) :521 -530.
10Arkenau HT, Chong G, Cunninghafl D, et al. Gemeitabine, eispla- tin and methylprednisolone for the treatment of patients with pe- ripheral T- Cell lymphoma: The Royal Marsden Hospital experi- ence [ J ]. Haematologiea ,2007,92 ( 2 ) : 271 - 272.
